TG Therapeutics, Inc.
- TGTX
- NASDAQ
- Biotechnology
- Biotech (Oncology/MS)
- Commercial-Stage Biopharma
$53.30
Today −1.24%Quote Oct 19, 2026, 08:00 PM UTC
−6.28%over the last month
Max drawdown −10.2%From 1-month high −8.3%3 months −1.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About TG Therapeutics
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions.
Where the money comes from
Q2 2026 revenue $240.3M
- Product$235.8M98.1%
- License Revenue$4.5M1.9%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
399
Market value
$8.16B
Quote Oct 19
Floor
$52.65
1.2% below price
Resistance
$54.06
1.4% above price
Price vs analyst targets
13 analysts
Lowest target
$78.00Highest target
$83.00
$78.00Highest target
$83.00
- Price $53.30
- Average target $80.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 51% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TGTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free